Pearl Therapeutics Secures Venture Debt
Pearl Therapeutics, a Redwood City, Calif.-based drug developer focused on respiratory disorders, has secured $8 million in venture debt financing from Oxford Finance Corp. and Silicon Valley Bank. The capital will be drawn down in two tranches. Pearl Therapeutics previously raised around $35.5 million in VC funding from Clarus Ventures, New Leaf Partners, 5AM Ventures and Nektar Therapeutics.
24 February 2009•3 mins read
